Podcast CME Course Information

Exam: Exam 140

Issue: July 24, 2012

Learning Objectives

Reducing in-hospital delay to 20 minutes in stroke thrombolysis

Upon completion of this podcast, the participant will be able to discuss some ideas for improving door-to-needle time for thrombolysis for acute stroke.

Recommended Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Core Competencies

• Medical Knowledge

Disclosures

Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.

Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.

Dr. Burns receives a stipend as Podcast Editor for Neurology® and performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc. AAN staff members editing the test (P Baskin, L Kleffman, K Skaja) have no disclosures. The CME Journal Editors, who have reviewed the exam, are Steven Lewis MD, who receives a stipend in his editorial capacity for Neurology, and James WM Owens Jr. MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology.

Dr. Meretoja has served as a consultant for Boehringer Ingelheim, and has received honoraria from Boehringer Ingelheim for speaking at educational symposia, travel expenses from H Lundbeck A/S, and research support from Sigrid Juselius Foundation, Biomedicum Helsinki Foundation, Instrumentarium Science Foundation, Yrjo Jahnsson Foundation, Paivikki and Sakari Sohlberg Foundation, Maire Taponen Foundation, Finnish-Norwegian Medical Foundation and Emil Aaltonen Foundation.

Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

Dr. Espay is supported by the K23 career development award (NIMH, 1K23MH092735); has received grant support from CleveMed/Great Lakes Neurotechnologies, Davis Phinney Foundation, and Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Solvay Pharmaceuticals, Inc., Abbott, Chelsea Therapeutics, TEVA Pharmaceutical Industries Ltd, Impax Pharmaceuticals, Solstice Neurosciences, and Eli Lilly and Company; and honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society. He serves as Assistant Editor of Movement Disorders and on the editorial boards of The European Neurological Journal and Frontiers in Movement Disorders.

Dr. Sperling received a speaker honorarium from Pfizer Inc.; serves on the editorial board of Alzheimer¹s disease and Associated Disorders; has served as a consultant for Roche, Janssen, Pfizer Inc, Bayer Schering Pharma, Eisai Inc., Satori, Kyowa Hakko Kirin, Bristol-Myers Squibb and Avid Radiopharmaceuticals, (unpaid); has received research support from Janssen, and Bristol-Myers Squibb, NIH/NIA, Alzheimer¹s Association, American Health Assistance Foundation, and an Anonymous Foundation.

The other participants had nothing to disclose.

CME Expiration

CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.

Accreditation

The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit™

The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.

Copyright

The American Academy of Neurology holds copyright for all materials in this exam.

Confidentiality

Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.

Hardware and Software Requirements

A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.

Start this exam